...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!


BREAKING: Loop Insights Announces Reseller Partnership And First Sale With Vend, A Global POS Company Used In 25,000 Stores Across 140 Countries

  • Announced the signing of a channel reseller partnership with global cloud-based Point-of-Sale (POS) company, Vend, as well as, the first sale to a Vend client
  • Vend is the first POS built for iOS and is now used in over 25,000 stores across 140 countries
  • Vend’s fast growth and global reach creates opportunities across the world for Loop and its technology in the retail vertical

Loop large

Hub On AGORACOM / Read Release


Message: So many questions...

Nice follow up post Cityslicker. Just a reminder, apabetalone is only one of thousands of BET inhibitors in their library. They have several follow on compounds ready to go into clinical development. Some may be improved versions of apabetalone for same indications. Some may be of differing BET protein or bromodomain specificity that are better suited for different indications.

Don't overlook the fact that this is the first company to take a BET inhibitor through Phase 3. No doubt in my mind that Resverlogix and Zenith are the world leaders in this field. Sell or license the apabetalone compound for a boatload of Benjamins, but keep the compound library and IP to further develop and capitalize on their huge head start in the bright future of bromodomain epigenetic drugs. Same logic for Zenith and ZEN-3694.


New Message
Please login to post a reply